Continue to Site

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » GI Dynamics touts no complications, lowered insulin in EndoBarrier reimplantation trial

GI Dynamics touts no complications, lowered insulin in EndoBarrier reimplantation trial

By

GI Dynamics

GI Dynamics (ASX:GID) today released data from an investigator-initiated study examining the safety and efficacy of its EndoBarrier after reimplantation for treatment for patients with type 2 diabetes and obesity, touting no complications and reduced insulin use.

The study followed 5 patients which all completed an initial course of EndoBarrier treatment for 12 months, after which the devices were explanted and patients were monitored for 4 months, after which the device was reimplanted for another 12 months.

Data from the trial indicated no complications and showed reductions in HbA1c levels and insulin during both implantation periods. HbA1c fell from a baseline of 9.1% to 6.7% after the 1st explant, and from 7.8% upon 2nd implantation to 7.1% upon the 2nd explant, the company said.

Insulin usage fell from a baseline of 60iU to 19iU at the 1st explant, and from 33iU to 20iU on the second round of implanting and explanting of the device, according to GI Dynamics.

“Although small, this study provided important information regarding serial usage of EndoBarrier. Re-implantation and re-explantation of the EndoBarrier device were performed on all five study subjects without any complications, and the early clinical data is promising. In addition, there was a significant reduction in insulin,” study primary investigator Dr. Jurgen Stein said in a prepared statement.

“The study shows early indication of efficacy to support multiple treatments utilizing EndoBarrier. Especially encouraging is the reduction of blood sugar and weight combined with concurrent reduction in insulin. We appreciate Dr. Stein’s efforts to conduct a study that adds such interesting insights into the growing body of evidence proving EndoBarrier safety and efficacy,” CEO & prez Scott Schorer said in a press release.

Last month, GI Dynamics released data from a meta-analysis of its EndoBarrier device, touting improved glycemic control in patients with type 2 diabetes and obesity. Data from the meta-analysis study was presented at the Digestive Disease Week meeting in Chicago.

In case you missed it

RSS From Medical Design & Outsourcing

  • Zimmer Biomet’s R&D team grows, manufacturing and total workforce shrinks after ZimVie spinoff
    Zimmer Biomet (NYSE:ZBH) has more R&D employees following the ZimVie spinoff but fewer total employees, including manufacturing employees and employees in the U.S. Warsaw, Indiana-based Zimmer Biomet spun its spine and dental business off as ZimVie (Nasdaq:ZIMV) in March 2022. Westminster, Colorado-based ZimVie said in its first-ever annual report this month that it has approximately… […]
  • This implantable fuel cell generates electricity from glucose
    A team of researchers developed an implantable fuel cell that uses excess glucose from tissue to generate electrical energy. By combining the fuel cell with artificial beta cells, the team produced insulin with the touch of a button. This effectively lowered blood glucose levels like the natural process in the pancreas. Given that current treatments… […]
  • Ulbrich launches all-in-one metals calculator and conversion app for manufacturers
    NEWS RELEASE: Ulbrich Launches All-in-One Metals Calculator and Conversion App for Manufacturers North Haven, Connecticut – Ulbrich Stainless Steels & Special Metals, the global leader in precision metal products, has launched its second mobile app — a metals calculator and conversion app with essential tools for engineers, purchasers, and other manufacturing personnel. The app is… […]
  • 11 diabetes tech startups you need to know
    The diabetes technology space is one that’s always innovating. From continuous glucose monitoring to insulin pumps and the artificial pancreas, we’ve seen a lot. Companies are looking for all kinds of ways to make their mark in the world of diabetes. Newer offerings include digital health, software, coaching and more. For companies still in their… […]
  • How bringing on suppliers reduced Tivic Health’s manufacturing costs
    Tivic Health Systems (Nasdaq:TIVC) announced today that a new partnership allowed it to significantly cut manufacturing costs. The company completed the supplier qualification and first article inspection of Microart Services. Microart is one of two new partners the company announced at the end of last year. San Francisco-based Tivic said the qualification and inspection helped… […]
  • Nearshoring in Mexico: the risks, challenges and benefits for medtech developers
    Mexico nearshoring is one way medtech manufacturers are addressing supply chain challenges that surfaced in the COVID-19 pandemic. Nearshoring is similar to offshoring, where a device developer moves some operations out of its home country to cut costs or access new markets. Nearshoring is just offshoring closer to home. Jorge Gonzalez Henrichsen, co-CEO of Brownsville,… […]
  • How virtual reality can improve pediatric care
    VR can help children overcome needle fear and allow pediatricians to improve medical care. Dr. Evelyn Chan, SmileyScope  Needles are involved in the most common office procedures and needle fear is nearly universal in young children. Virtual reality (VR) technology might offer a solution. Studies show nearly two-thirds of children and one-fourth of adults have… […]
  • Opportunity awaits at DeviceTalks Boston
    Medtech faces many challenges, but every challenge presents an opportunity — and DeviceTalks Boston will focus on making the best of them. Leaders like to say every challenge presents an opportunity. It sounds uplifting and offers the benefits of being at least partially true, in life and in medtech. It’s fair to say the medical… […]
  • Ashley McEvoy joins J&J’s top-paid executives
    Johnson & Johnson (NYSE:JNJ) has for the first time disclosed its pay package for EVP Ashley McEvoy, the worldwide chair of medical device subsidiary J&J Medtech. McEvoy’s $7.4 million in total compensation could make her the highest-paid woman in medtech. She’s not the highest-paid woman at J&J, however. J&J reported nearly $8.8 million in total… […]
  • How surgical robotics safety systems prevent patient harm
    Surgical robotics safety systems are likely on the mind of anyone going under the knife of these complex machines. Reliability, biocompatibility and other standard medical device safety concerns still apply. But a few areas stand out in robotic-assisted surgery, said Mark Toland, CEO at surgical robotics developer Medical Microinstruments (MMI). “Most of the safety elements… […]
  • FDA issues final rules for transitioning away from COVID-19 authorizations
    The FDA this week announced a transition plan for medical devices that fall with the emergency use authorization enforcement policies issued during the COVID-19 pandemic. Guidances that set forth COVID-19-related enforcement policies for certain devices initially stated that they were intended to remain in effect for the duration of the pandemic declaration. The declaration is… […]

Copyright © 2023 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy